# Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea

Study · id `cardio:ct-nct01392677` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01392677](<https://clinicaltrials.gov/study/NCT01392677>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01392677

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 311 participants.

## Technical summary

Registry record NCT01392677. Randomized; quadruple masking; primary purpose treatment. Start 2011-10 (registry gives no type); primary completion 2013-01 (actual). Results posted on 2013-12-27.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 311 participants (enrolled count; ClinicalTrials.gov record NCT01392677, source copy `cardio:ctgov-nct01392677-2014-03-12`, retrieved 2026-10-26)
- Start date: 2011-10 (registry gives no type) (ClinicalTrials.gov record NCT01392677, source copy `cardio:ctgov-nct01392677-2014-03-12`, retrieved 2026-10-26)
- Primary completion: 2013-01 (actual) (ClinicalTrials.gov record NCT01392677, source copy `cardio:ctgov-nct01392677-2014-03-12`, retrieved 2026-10-26)
- Completion: 2013-08 (actual) (ClinicalTrials.gov record NCT01392677, source copy `cardio:ctgov-nct01392677-2014-03-12`, retrieved 2026-10-26)
- Results first posted: 2013-12-27 (ClinicalTrials.gov record NCT01392677, source copy `cardio:ctgov-nct01392677-2014-03-12`, retrieved 2026-10-26)
- Countries: Canada; Czechia; Germany; Poland; Slovakia; Spain (ClinicalTrials.gov record NCT01392677, source copy `cardio:ctgov-nct01392677-2014-03-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01392677-2014-03-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea
- Condition: Type 2 Diabetes Mellitus
- Condition: High HbA1c Level
- Condition: Inadequate Glycaemic Control
- Intervention (Drug): dapagliflozin
- Intervention (Drug): placebo
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY
- Collaborator: Bristol-Myers Squibb
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Dapagliflozin (`cardio:dapagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)
- Registry lists this organization as a collaborator: Bristol-Myers Squibb (`cardio:org-bristol-myers-squibb`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial (`cardio:pubmed-25592197`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 0154aeac30837cc9939f62ae6cdbed7d6335c054499b69941cf94fcdff1b8d2d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
